Cytek Biosciences, Inc. Common Stock vs. 10x Genomics, Inc. Class A Common Stock
CTKB
Cytek Biosciences, Inc. Common Stock
$4.89 +1.24%
VS TXG10x Genomics, Inc. Class A Common Stock
$76.60 -0.48%
Cytek Biosciences, Inc. Common Stock and 10x Genomics, Inc. Class A Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| CTKB | TXG | |
|---|---|---|
| Market Cap | $627.82 million | $10.03 billion |
| Revenue (TTM) | — | $616.91 million |
| Net Income (TTM) | — | $-75,125,000 |
TXG leads on 1 of 1 size & scale factors.
Valuation
| CTKB | TXG | |
|---|---|---|
| Price / Book | — | 12.15 |
| Price / Sales | — | 16.26 |
CTKB and TXG split the valuation factors evenly.
Profitability
| CTKB | TXG | |
|---|---|---|
| Net Margin | — | -12.18% |
| Return on Equity | — | -9.10% |
CTKB and TXG split the profitability factors evenly.
Risk & Sentiment
| CTKB | TXG | |
|---|---|---|
| Short Interest | 0.01% | 0.42% |
CTKB leads on 1 of 1 risk & sentiment factors.
Dig deeper: CTKB overview, CTKB financials, TXG overview, TXG financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.